HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chatal, J.-F. Articles by Guillard, Y. Search for Related Content PubMed PubMed Citation Articles by Chatal, J.-F. Articles by Guillard, Y.

Immunoscintigraphy of Recurrences of Gynecologic Carcinomas

Unité Inserm U-211, UER de Médecine
Centre René Gauducheau, Quai Moncousu Nantes
Compagnie ORIS Industrie Gif sur Yvette, France

Correspondence: For reprints contact: Jean-François Chatal, MD, U.211 Inserm, UER de Médecine, 1, rue Gaston Veil, 44035 Nantes Cedex 01, France.

ABSTRACT

In a first, retrospective study, 15 patients with known ovarian carcinoma were injected with ¹³¹I-OC 125 F(ab')₂ monoclonal antibody (MAb). The sensitivity of immunoscintigraphy based on the number of the tumor sites was 67% (12/18). In a second, prospective study, 29 patients with gynecologic carcinoma were injected with ¹³¹I-OC 125 F(ab')₂ (24) or ¹³¹I-19-9 F(ab)₂ (5) MAbs according to the histologic type. Based on the number of tested anatomic sites, sensitivity was 72% and specificity 86%. In two patients injected with both ¹³¹I-OC-125 F(ab')₂ and ¹²⁵I-NS F(ab')₂ (nonspecific immunoglobulin) 1 and 4 days before tumor resection, tumor uptake of the specific antibody was 2.2 and 4.5 times greater than that of NS. Immunoscintigraphic results were complementary with those of ultrasonography and computed tomography. Finally, in one patient injected successively with ¹³¹I-OC 125 F(ab')₂ and ¹¹¹In-DTPA-OC 125 F(ab')₂, the recurrent tumor was visualized with both radionuclides, with ¹¹¹In providing better abdominal tumor contrast but causing much greater liver radioactivity than ¹³¹I.

This article has been cited by other articles:

				S. P. Lubic, D. A. Goodwin, C. F. Meares, C. Song, M. Osen, and M. Hays Biodistribution and Dosimetry of Pretargeted Monoclonal Antibody 2D12.5 and Y-Janus-DOTA in BALB/c Mice with KHJJ Mouse Adenocarcinoma J. Nucl. Med., April 1, 2001; 42(4): 670 - 678. [Abstract] [Full Text]